222 related articles for article (PubMed ID: 31850487)
1. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
[TBL] [Abstract][Full Text] [Related]
2. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaceutical product quality control and good manufacturing practices].
Hiyama Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
[TBL] [Abstract][Full Text] [Related]
4. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
5. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
[TBL] [Abstract][Full Text] [Related]
6. Identifying and assessing highly hazardous drugs within quality risk management programs.
Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
[TBL] [Abstract][Full Text] [Related]
7. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
[TBL] [Abstract][Full Text] [Related]
8. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
10. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
Geyer ARC; Sousa VD; Silveira D
PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
[TBL] [Abstract][Full Text] [Related]
11. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
12. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2012; (970):1-235, back cover. PubMed ID: 22894011
[TBL] [Abstract][Full Text] [Related]
13. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
14. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2011; (961):1-428, back cover. PubMed ID: 21699061
[TBL] [Abstract][Full Text] [Related]
15. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
[TBL] [Abstract][Full Text] [Related]
16. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2014; (986):1-387, back cover. PubMed ID: 24964711
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical GMP: past, present, and future--a review.
Patel KT; Chotai NP
Pharmazie; 2008 Apr; 63(4):251-5. PubMed ID: 18468382
[TBL] [Abstract][Full Text] [Related]
18. [Accession to the PIC/S and pharmaceutical quality system in Japan].
Katori N
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):22-35. PubMed ID: 25707200
[TBL] [Abstract][Full Text] [Related]
19. Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2016 Aug; 81(169):60169-224. PubMed ID: 27580511
[TBL] [Abstract][Full Text] [Related]
20. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
